Weight loss program using mobile health technology for obese young patients after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study focuses on obese adolescents and young adults aged 13-30 who have undergone hematopoietic stem cell transplantation (HSCT). Participants will engage in a mobile health (mHealth) weight loss intervention that includes coaching and support over a four-month period. The study will assess changes in body mass index (BMI), metabolic metrics, and eating behaviors through regular check-ins and the use of a dedicated app. A total of 20 patients will be recruited from the hematology/oncology clinic at UCLA Mattel Children's Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 13 and ≤ 30 years old with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study.
* Both male and female patients will be eligible.
* Patients must classify as obese, represented as Body mass index \[BMI\] ≥85th percentile for age and gender.
* Patients must also be able to read English since the app intervention is only available in English form.

Exclusion Criteria:

* Patients who are ≤ 13 or ≥ 30 years old are not eligible for the study.
* Patients who are \< 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are \>100 days post-transplant at their next consultation that falls within the enrollment window.
* Patients whose BMI does not fall under the obese category will be excluded.
* No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation.

Where it's running

• UCLA Mattel Children's Hospital
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Theodore B Moore, MD — UCLA Health
• Study coordinator: Belen Ramirez
• Email: belenramirez@mednet.ucla.edu
• Phone: 3102670425

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.